This trial is evaluating whether Dexamethasone will improve 1 primary outcome, 9 secondary outcomes, and 2 other outcomes in patients with Multiple Myeloma. Measurement will happen over the course of 5 Years.
This trial requires 188 total participants across 2 different treatment groups
This trial involves 2 different treatments. Dexamethasone is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"It is difficult to determine the cause of MM, but it may be a combination of genetic and environmental factors. The risk of developing MM can be significantly reduced by cigarette smoking, avoiding ultraviolet exposure (including the sun), and drinking alcohol in moderation. Although exposure to certain infectious diseases has been linked to some cases of MM, its significance is unclear, and no major environmental toxins have been unequivocally linked." - Anonymous Online Contributor
"Many signs of osteolytic disease were present. A low B cell count may be present. Oedema may occur which may be symmetrical or distributed and may be associated with renal dysfunction or anaemia. In the setting of bone pain, bone pain may be tender to palpation.\n" - Anonymous Online Contributor
"There are 20,600 to 50,850 new cases of MM a year in this country, about two thirds of which are patients in their seventies. MM accounted for around 23% of all patients with multiple myeloma (NIA Registry of the National Institute of Arthritis and Muscular Dystrophy). Approximately 12,000 patients with MM die from the disease annually, making it the second most lethal malignancy in patients older than 65 years (Census bureau, Bethesda, MD, 2005; Cancer and Comorbidity Report, 2010)." - Anonymous Online Contributor
"Multiple myeloma affects about 2% of people over the age of 35 and a lifetime risk of about 2–4%. By comparison, the lifetime risk of lung cancer is about 8%. This is a summary of the current situation based on latest data, although numbers are expected to grow as more people diagnosed with multiple myeloma die. There has been an increase in new diagnoses since the 1970s, probably partly due to improvements in detection. Better control of the disease may have also been responsible for better survival rates. Patients usually progress to a chronic form of the disease and have a limited lifespan." - Anonymous Online Contributor
"A high fraction of hospitalized [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) patients are receiving treatment that includes more than four chemotherapy regimens (mediastinal radiotherapy and proteasome inhibitors like bortezomib) and autologous stem cell transplantation for non-progressive disease. Although no therapies have proven effective for improving long-term progression-free survival in patients with myeloma, more than 60% of patients progress with disease in the 10 years following their first treatment." - Anonymous Online Contributor
"Currently no treatment for MM can cure the disease because it follows the paradigm that chronic malignancy is never cured and cannot be. However, a cure for MM is a realistic goal to which the MM community and clinical laboratories and investigators may be striving. New therapies should allow MM to become manageable rather than be the last manifestation of malignant transformation." - Anonymous Online Contributor
"The use of dexamethasone is now accepted in the United States as a standard treatment for patients with multiple myeloma refractory to treatment with ATRA alone and with anthracycline based chemotherapy.\n" - Anonymous Online Contributor
"Dexamethasone has been used in clinical trials to treat various conditions. It has many uses which include the following: (1) as part of chemotherapy; (2) in combination with methotrexate, 5-FU, vincristine, procarbazine and cyclophosphamide for the treatment of cutaneous T-cell lymphoma and non-Hodgkin lymphoma; and (3) in combination with cytotoxics, such as methotrexate, prednisone, vismodegib, and etoposide in patients with multiple myeloma who have failed standard chemotherapy." - Anonymous Online Contributor
"Although the clinical features of multiple myeloma and its spread are extremely variable, the disease behaves in a predictable fashion to a higher or lower degree in anyone." - Anonymous Online Contributor
"Side effects of dexamethasone are common and include nausea, diarrhea, acne, hair loss, headache, muscle and joint swelling, muscle weakness or cramping, and hair color changes. There was no evidence of increased risk of osteoporosis or other side effects in multiple myeloma patients who had taken dexamethasone as part of chemotherapy. More research is needed to better understand the adverse effects of dexamethasone in multiple myeloma." - Anonymous Online Contributor
"Clinically appropriate patients who are eligible for a clinical trial should be counseled about trial enrollment and provided with the opportunity for an informed decision about treatment. To achieve the best-value clinical outcome, both clinical investigators and clinicians need to implement treatment according to the preferences of patients." - Anonymous Online Contributor
"DEX can be safely initiated and dosed over 6 months. Withdrawal is associated with a number of adverse events, of which most are reversible. DEX is a safer, more rapid and effective treatment for myeloma patients over steroids or IMI." - Anonymous Online Contributor